Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.4 percent. This is a 3233.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $1.299 million which missed the analyst consensus estimate of $13.886 million by 90.65 percent. This is a 96.53 percent decrease over sales of $37.398 million the same period last year.